{
 "license":"CC BY 4.0",
 "source":"https://weighweekly.com/",
 "note":"Mean percent body-weight change vs baseline. Published endpoint values are exact; intermediate weeks are read from published trial figures and interpolated. Treatment-policy estimand where available.",
 "trials":[
  {"id":"sema24","drug":"semaglutide 2.4 mg weekly","brand":"Wegovy","trial":"STEP 1","citation":"Wilding JPH et al. NEJM 2021;384:989-1002","endpoint_week":68,"endpoint_mean_pct":-14.9,"placebo_pct":-2.4,"pct_losing_5":86,"curve":[[0,0],[4,-2.0],[8,-4.0],[12,-6.0],[16,-7.6],[20,-9.0],[28,-11.0],[36,-12.5],[44,-13.6],[52,-14.3],[60,-14.7],[68,-14.9]]},
  {"id":"tirz5","drug":"tirzepatide 5 mg weekly","brand":"Zepbound","trial":"SURMOUNT-1","citation":"Jastreboff AM et al. NEJM 2022;387:205-216","endpoint_week":72,"endpoint_mean_pct":-15.0,"placebo_pct":-3.1,"curve":[[0,0],[4,-2.4],[8,-4.6],[12,-6.8],[20,-9.9],[28,-12.0],[36,-13.5],[44,-14.4],[52,-14.8],[60,-15.0],[72,-15.0]]},
  {"id":"tirz10","drug":"tirzepatide 10 mg weekly","brand":"Zepbound","trial":"SURMOUNT-1","citation":"Jastreboff AM et al. NEJM 2022;387:205-216","endpoint_week":72,"endpoint_mean_pct":-19.5,"placebo_pct":-3.1,"curve":[[0,0],[4,-2.5],[8,-4.9],[12,-7.3],[20,-10.9],[28,-13.7],[36,-15.9],[44,-17.4],[52,-18.5],[60,-19.1],[72,-19.5]]},
  {"id":"tirz15","drug":"tirzepatide 15 mg weekly","brand":"Zepbound","trial":"SURMOUNT-1","citation":"Jastreboff AM et al. NEJM 2022;387:205-216","endpoint_week":72,"endpoint_mean_pct":-20.9,"placebo_pct":-3.1,"pct_losing_5":91,"curve":[[0,0],[4,-2.6],[8,-5.0],[12,-7.5],[20,-11.0],[28,-14.0],[36,-16.5],[44,-18.3],[52,-19.5],[60,-20.3],[72,-20.9]]},
  {"id":"oral25","drug":"oral semaglutide 25 mg daily","brand":"Wegovy (pill)","trial":"OASIS 4","citation":"Wharton S et al. NEJM 2025","endpoint_week":64,"endpoint_mean_pct":-13.6,"placebo_pct":-2.2,"curve":[[0,0],[4,-1.8],[8,-3.6],[12,-5.4],[16,-6.9],[20,-8.2],[28,-10.1],[36,-11.5],[44,-12.5],[52,-13.1],[64,-13.6]]},
  {"id":"lira3","drug":"liraglutide 3.0 mg daily","brand":"Saxenda","trial":"SCALE","citation":"Pi-Sunyer X et al. NEJM 2015;373:11-22","endpoint_week":56,"endpoint_mean_pct":-8.0,"placebo_pct":-2.6,"curve":[[0,0],[4,-1.5],[8,-2.8],[12,-3.9],[16,-4.8],[20,-5.6],[28,-6.6],[36,-7.3],[44,-7.7],[52,-7.9],[56,-8.0]]}
 ],
 "head_to_head":[{"trial":"SURMOUNT-5","citation":"Aronne LJ et al. NEJM 2025","week":72,"tirzepatide_pct":-20.2,"semaglutide_pct":-13.7}],
 "protein_target_g_per_kg":[1.2,1.6]
}